Skip to main content
  1. Right Decisions
  2. GGC - Clinical Guidelines
  3. Maternity
  4. Back
  5. Common obstetric problems, intrapartum labour ward
  6. Postpartum Hypertension, Guideline for Management (322)
Important: please update your RDS app to version 4.7.3

Welcome to the March 2025 update from the RDS team

1.     RDS issues - resolutions

1.1 Stability issues - Tactuum implemented a fix on 24th March which we believe has finally addressed the stability issues experienced over recent weeks.  The issue seems to have been related to the new “Tool export” function making repeated calls for content when new toolkit nodes were opened in Umbraco. No outages have been reported since then, and no performance issues in the logs, so fingers crossed this is now resolved.

1.2 Toolkit URL redirects failing– these were restored manually for the antimicrobial calculators on the 13th March when the issue occurred, and by 15th March for the remainder. The root cause was traced to adding a new hostname for an app migrated from another health board and made live that day. This led to the content management system automatically creating internal duplicate redirects, reaching the maximum number of permitted redirects and most redirects therefore ceasing to function.

This issue should not happen again because:

  • All old apps are now fully migrated to RDS. The large number of migrations has contributed to the high number of automated redirects.
  • If there is any need to change hostnames in future, Tactuum will immediately check for duplicates.

1.3 Gentamicin calculators – Incidents have been reported incidents of people accessing the wrong gentamicin calculator for their health board.  This occurs when clinicians are searching for the gentamicin calculator via an online search engine - e.g. Google - rather than via the health board directed policy route. When accessed via an external search engine, the calculator results are not listed by health board, and the start page for the calculator does not make it clearly visible which health board calculator has been selected.

The Scottish Antimicrobial Prescribing Group has asked health boards to provide targeted communication and education to ensure that clinicians know how to access their health board antimicrobial calculators via the RDS, local Intranet or other local policy route. In terms of RDS amendments, it is not currently possible to change the internet search output, so the following changes are now in progress:

  • The health board name will now be displayed within the calculator and it will be made clear which boards are using the ‘Hartford’ (7mg/kg) higher dose calculator
  • Warning text will be added to the calculator to advise that more than one calculator is in use in NHS Scotland and that clinicians should ensure they access the correct one for their health board. A link to the Right Decision Service list of health board antimicrobial prescribing toolkits will be included with the warning text. Users can then access the correct calculator for their Board via the appropriate toolkit.

We would encourage all editors and users to use the Help and Support standard operating procedure and the Editors’ Teams channel to highlight issues, even if you think they may be temporary or already noted. This helps the RDS team to get a full picture of concerns and issues across the service.

 

2.     New RDS presentation – RDS supporting the patient journey

A new presentation illustrating how RDS supports all partners in the patient journey – multiple disciplines across secondary, primary, community and social care settings – as well as patients and carers through self-management and shared decision-making tools – is now available. You will find it in the Promotion and presentation resources for editors section of the Learning and support toolkit.

3.     User guides

A new user guide is now available in the Guidance and tips section of Resources for providers within the Learning and Support area, explaining how to embed content from Google Calendar, Google Maps, Daily Motion, Twitter feeds, Microsoft Stream and Jotforms into RDS pages. A webinar for editors on using this new functionality is scheduled for 1 May 3-4 pm (booking information below.)

A new checklist to support editors in making all the checks required before making a new toolkit live is now available at the foot of the “Request a new toolkit” standard operating procedure. Completing this checklist is not a mandatory part of the governance process, but we would encourage you to use it to make sure all the critical issues are covered at point of launch – including organisational tags, use of Alias URLs and editorial information.

4.Training sessions for RDS editors

Introductory webinars for RDS editors will take place on:

  • Tuesday 29th April 4-5 pm
  • Thursday 1st May 4-5 pm

Special webinar for RDS editors – 1 May 3-4 pm

This webinar will cover:

  1. a) Use of the new left hand navigation option for RDS toolkits.
  2. b) Integration into RDS pages of content from external sources, including Google Calendar, Google Maps and simple Jotforms calculators.

Running usage statistics reports using Google analytics

  • Wednesday 23rd April 2pm-3pm
  • Thursday 22nd May 2pm-3pm

To book a place on any of these webinars, please contact Olivia.graham@nhs.scot providing your name, role, organisation, title and date of the webinar you wish to attend.

5.New RDS toolkits

The following toolkits were launched during March 2025:

SIGN guideline - Prevention and remission of type 2 diabetes

Valproate – easy read version for people with learning disabilities (Scottish Government Medicines Division)

Obstetrics and gynaecology induction toolkit (NHS Lothian) – password-protected, in pilot stage.

Oral care for care home and care at home services (Public Health Scotland)

Postural care in care homes (NHS Lothian)

Quit Your Way Pregnancy Service (NHS GGC)

 

6.New RDS developments

Release of the redesign of RDS search and browse, archiving and version control functionality, and editing capability for shared content, is now provisionally scheduled for early June.

The Scottish Government Realistic Medicine Policy team is leading development of a national approach to implementation of Patient-Reported Outcome Measures (PROMs) as a key objective within the Value Based Health and Care Action Plan. The Right Decision Service has been commissioned to deliver an initial version of a platform for issuing PROMs questionnaires to patients, making the PROMs reports available from patient record systems, and providing an analytics dashboard to compare outcomes across services.  This work is now underway and we will keep you updated on progress.

The RDS team has supported Scottish Government Effective Prescribing and Therapeutics Division, in partnership with Northern Ireland and Republic of Ireland, in a successful bid for EU funding to test develop, implement and assess new integrated care pathways for polypharmacy, including pharmacogenomics. As part of this project, the RDS will be working with NHS Tayside to test extending the current polypharmacy RDS decision support in the Vision primary care electronic health record system to include pharmacogenomics decision support.

7. Implementation projects

We have just completed a series of three workshops consulting on proposed improvements to the Being a partner in my care: Realistic Medicine together app, following piloting on 10 sites in late 2024. This app has been commissioned by Scottish Government Realistic Medicine to support patients and citizens to become active partners in shared decision-making and encouraging personalised care based on outcomes that matter to the person. We are keen to gather more feedback on this app. Please forward any feedback to ann.wales3@nhs.scot

 

 

Postpartum Hypertension, Guideline for Management (322)

Warning

Please report any inaccuracies or issues with this guideline using our online form

General points

  • There is a physiological rise in blood pressure in the postnatal period, often reaching a peak at day 3-6 postnatal
  • BP should be measured at least daily for the first 2 days after birth
  • BP should be measured at least once between day 3 and 5 after birth
  • Systolic blood pressure is an important risk factor for stroke
  • Severe hypertension (≥160/110 mmHg) must be treated
  • BP persistently ≥150/100 mmHg should be treated
  • Eclamptic seizures can occur in the postnatal period, but are less likely after the third postnatal day. When they do occur this is frequently associated with prodromal signs and symptoms (commonly headache or visual disturbance), although not necessarily hypertension
  • Avoid methyldopa in the postnatal period due to its association with postnatal depression
  • Nonsteroidal anti-inflammatory drugs (NSAIDs) should be avoided in the presence of hypertension that is difficult to control, oliguria or impaired renal function

There are 3 groups of women with postpartum hypertension

  • Ante-natal Pregnancy Induced Hypertension (PIH) or pre-eclampsia (PET)
  • Known chronic hypertension
  • ‘De novo’ hypertension

 

BP ≥160/110 mmHg or MAP >125 requires treatment

Severe hypertension in previously normotensive women is an obstetric emergency. If the patient is clinically stable oral agents can be used in the first instance. Rarely, the clinical situation will merit IV therapy in the postnatal period-as per the severe pre-eclampsia guideline

BP ≥150/100 mmHg commence regular antihypertensives

** In cases of chronic hypertension the response to blood pressure readings should be tailored to the individual case. In women with chronic hypertension, pre-dating their pregnancy, they have reset their cerebral auto-regulation mechanism and will not be at as great a risk of CVA from a systolic reading of 160mmHg compared to a previously normotensive women

1st line 

  • Offer Enalapril to treat hypertension with appropriate monitoring of maternal renal function (including serum K+)

2nd Line

  • If BP not controlled with single medicine, consider a combination of Nifedipine (or Amlodipine) and Enalapril

If this combination is not tolerated or is ineffective, consider either

3rd Line

  • Adding Atenolol or Labetalol (preferred if breast feeding) to the combination treatment or
  • Swapping 1 of the medicines already being used for Atenolol or Labetalol (preferred if breast feeding)

Women of Black African or African-Caribbean origin 

Monotherapy with ACE inhibitors or B blockers is less effective in this patient group.  Therefore, consider the following as first line agents:

  • Nifedipine
  • Amlodipine if the woman has previously used this to successfully control her BP

Postnatal hypertension drugs and dosage table

Important points to note:

  • When treating women in the postnatal period use medicines that are once daily if possible
  • Where possible, avoid using diuretics or angiotensin receptor blockers to treat hypertension in women who are breastfeeding or expressing
  • In breastfeeding, antihypertensives can pass into breast milk. However, most medicines only lead to low levels in breast milk, therefore the amounts taken in by babies are very small and would be unlikely to have any clinical effect. The exception is atenolol and it is preferable to use an alternative agent in women who are breastfeeding
  • ACE inhibitors can be used in breastfeeding women – enalapril is the drug of choice. In the context of severe preterm delivery discussion with the neonatal team may be appropriate
  • When discharged home, advise women who are breastfeeding and taking antihypertensive medication to monitor their baby for drowsiness, lethargy, pallor, cold peripheries or poor feeding

  • Maintain BP <150/100 , ideally <140/90 mmHg in the postnatal period
  • For patients with end-organ damage (e.g. renal disease or diabetes) aim for target BP ≤ 130/80 mmHg
  • For patients with chronic hypertension aim for target BP ≤ 135/85 mmHg
  • Outpatient BP monitoring should be arranged e.g. Community Midwife, DCU or GP
  • BP <130/80 mmHg-reduce medication (see appendix 1)
  • BP <120/70 mmHg - stop medication

  • Inform own consultant of any patient being discharged on antihypertensive medication.
  • Women with chronic hypertension, or hypertension secondary to other medical conditions, will have a care plan defined by their obstetric/medical team.

  • For women with PIH / PET:
    • Outpatient monitoring should be arranged - Community Midwife or GP.
    • Alternatively, home BP monitoring via DCU can be requested.
    • The care plan for home BP monitoring, to be documented by medical staff in BadgerNet, should include frequency of BP recordings; target BP and thresholds for stopping treatment and indications for referral to secondary care for BP review.
    • The Postnatal Discharge Letter for Women with Hypertension in Pregnancy should be completed and information sent to GP

  • On discharge, the case notes of any woman whose pregnancy has been complicated by hypertension should be sent to the relevant consultant to decide if the woman requires consultant postnatal review at 6-8 weeks postpartum. If this is not felt to be required the woman should be reviewed by her GP at 6-8 weeks postpartum.

  • Women who have had PIH / PET and remain on antihypertensive medications 2 weeks after transfer to community care should have a GP/medical review.
  • Women who have had PIH / PET and remain on treatment at 12 weeks postpartum, should have a specialist medical assessment of their hypertension.

Postnatal hypertension management in hospital - flowchart

Postnatal hypertension management in the community - flowchart

Suggested regime for reducing antihypertensive medication

Editorial Information

Last reviewed: 27/02/2024

Next review date: 08/02/2029

Author(s): Claire McCormack.

Version: 3

Co-Author(s): Janet Brennand.

Approved By: Maternity Clinical Governance Group

Document Id: 322

References

NICE. Hypertension in pregnancy: diagnosis and management. [NG133] June 2019

Smith M et al. Management of postpartum hypertension. The Obstetrician & Gynaecologist 2013; 15:45-50

Handbook of Obstetric Medicine 5th Edition, Nelson-Piercy